Cargando…

IDO Inhibition Facilitates Antitumor Immunity of Vγ9Vδ2 T Cells in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) escape from immune-mediated destruction was associated with immunosuppressive responses that dampened the activation of tumor-infiltrating CD8 and γδ T cells. TNBC had a higher level of programmed cell death 1-ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase (IDO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Peng, Wu, Ruan, Li, Ke, Yuan, Wenhui, Zeng, Chuqian, Zhang, Yuting, Wang, Xiao, Zhu, Xinhai, Zhou, Jianjun, Li, Ping, Gao, Yunfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351331/ https://www.ncbi.nlm.nih.gov/pubmed/34381711 http://dx.doi.org/10.3389/fonc.2021.679517

Ejemplares similares

Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity
por: Kabelitz, Dieter, et al.
Publicado: (2013)

Characteristics of peripheral Vγ2Vδ2 T cells in interferon-γ release assay negative pulmonary tuberculosis patients
por: Yan, Liping, et al.
Publicado: (2018)

Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients
por: Lin, Mao, et al.
Publicado: (2020)

CD137 Costimulation Enhances the Antitumor Activity of Vγ9Vδ2-T Cells in IL-10-Mediated Immunosuppressive Tumor Microenvironment
por: Pei, Yujun, et al.
Publicado: (2022)

The antitumor activity of human Vγ9Vδ2 T cells is impaired by TGF-β through significant phenotype, transcriptomic and metabolic changes
por: Rafia, Chirine, et al.
Publicado: (2023)

Mapping of γ/δ T cells reveals Vδ2+ T cells resistance to senescence
por: Xu, Weili, et al.
Publicado: (2018)

GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer
por: Wei, Jin-Li, et al.
Publicado: (2021)

Sensing of Pyrophosphate Metabolites by Vγ9Vδ2 T Cells
por: Gu, Siyi, et al.
Publicado: (2015)

Role of Vγ9vδ2 T lymphocytes in infectious diseases
por: Gay, Laetitia, et al.
Publicado: (2022)

Myeloid-Derived Suppressor Cells Specifically Suppress IFN-γ Production and Antitumor Cytotoxic Activity of Vδ2 T Cells
por: Sacchi, Alessandra, et al.
Publicado: (2018)

Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity
por: Accardo-Palumbo, Antonina, et al.
Publicado: (2010)

1α,25(OH)(2)D(3) reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells
por: Li, Peng, et al.
Publicado: (2022)

B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma
por: Wang, Yi, et al.
Publicado: (2023)

Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy
por: Li, Peng, et al.
Publicado: (2022)

Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer
por: Hoeres, Timm, et al.
Publicado: (2018)

Development and Selection of the Human Vγ9Vδ2(+) T-Cell Repertoire
por: Willcox, Carrie R., et al.
Publicado: (2018)

The PPARα pathway in Vγ9Vδ2 T cell anergy
por: Poupot, Mary, et al.
Publicado: (2014)

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy
por: Ridgley, Laura A., et al.
Publicado: (2023)

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
por: Nandre, Rahul, et al.
Publicado: (2022)

Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme
por: Lee, Mijeong, et al.
Publicado: (2019)

The human Vδ2(+) T-cell compartment comprises distinct innate-like Vγ9(+) and adaptive Vγ9(-) subsets
por: Davey, Martin S., et al.
Publicado: (2018)

Role of Vγ9Vδ2+ γδ T cells in juvenile idiopathic arthritis
por: Gerstein, M, et al.
Publicado: (2008)

BTLA, a key regulator of Vγ9Vδ2 T-cell proliferation
por: Gertner-Dardenne, Julie, et al.
Publicado: (2013)

An Update on the Molecular Basis of Phosphoantigen Recognition by Vγ9Vδ2 T Cells
por: Herrmann, Thomas, et al.
Publicado: (2020)

Control of CD56 expression and tumor cell cytotoxicity in human Vγ2Vδ2 T cells
por: Urban, Elizabeth M, et al.
Publicado: (2009)

Nanocages engineered from Bacillus Calmette-Guerin facilitate protective Vγ2Vδ2 T cell immunity against Mycobacterium tuberculosis infection
por: Pi, Jiang, et al.
Publicado: (2022)

Chitosan Nanoparticles Strengthen Vγ9Vδ2 T-Cell Cytotoxicity Through Upregulation Of Killing Molecules And Cytoskeleton Polarization
por: Lin, Li, et al.
Publicado: (2019)

A Quantitative Deficiency in Peripheral Blood Vγ9Vδ2 Cells Is a Negative Prognostic Biomarker in Ovarian Cancer Patients
por: Thedrez, Aurélie, et al.
Publicado: (2013)

B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells
por: Lu, Huimin, et al.
Publicado: (2020)

S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model
por: Miyajima, Noriyuki, et al.
Publicado: (2021)

Human Vγ9Vδ2 T Lymphocytes in the Immune Response to P. falciparum Infection
por: Howard, Jennifer, et al.
Publicado: (2018)

Mistletoe-Extract Drugs Stimulate Anti-Cancer Vγ9Vδ2 T Cells
por: Ma, Ling, et al.
Publicado: (2020)

Functional Phenotypes of Human Vγ9Vδ2 T Cells in Lymphoid Stress Surveillance
por: Nussbaumer, Oliver, et al.
Publicado: (2020)

Epidemiology of Deltacoronaviruses (δ-CoV) and Gammacoronaviruses (γ-CoV) in Wild Birds in the United States
por: Paim, Francine C., et al.
Publicado: (2019)

Effector Vγ9Vδ2 T cell response to congenital Toxoplasma gondii infection
por: Ma, Ling, et al.
Publicado: (2021)

Generation and application of TGFβ-educated human Vγ9Vδ2 T cells
por: Parente-Pereira, Ana C., et al.
Publicado: (2022)

Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
por: Giannotta, Claudia, et al.
Publicado: (2023)

Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy
por: Du, Shou-Hui, et al.
Publicado: (2016)

Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
por: Alnaggar, Mohammed, et al.
Publicado: (2019)

Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome
por: Toia, Francesca, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_266bhqq8c1etplktfgkkl00t8k